Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 9/20 | 0.71 |
| ▸ | INSR | P06213 | 5/20 | 0.71 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.71 |
| ▸ | IGF1R | P08069 | 4/20 | 0.71 |
| ▸ | MET | P08581 | 4/20 | 0.71 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.71 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.71 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.71 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.71 |
| ▸ | CDK7 | P50613 | 2/20 | 0.71 |
| ▸ | CDC7 | O00311 | 1/20 | 0.71 |
| ▸ | PLK4 | O00444 | 1/20 | 0.71 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.71 |
| ▸ | AURKA | O14965 | 1/20 | 0.71 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.71 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.71 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.71 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.71 |
| ▸ | JAK2 | O60674 | 1/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30631285 | 1.00 | ALK (0.71) | ALKINSRPTK2IGF1RMET | |
| Hydrochloric Acid SCHEMBL2592568 | 0.99 | ALK (0.70) | ALKINSRPTK2IGF1RMET | |
| SCHEMBL2594676 | 0.94 | ULK1 (0.70) | ALKINSRPTK2IGF1RMET | |
| SCHEMBL18350631 | 0.87 | ALK (0.85) | ALKINSRPTK2IGF1RMET | |
| SCHEMBL30631286 | 0.86 | ZAP70 (0.67) | ALKINSRPTK2IGF1RMET | |
| SCHEMBL2589418 | 0.86 | ZAP70 (0.67) | ALKINSRPTK2IGF1RMET | |
| SCHEMBL14982991 | 0.86 | ULK1 (0.72) | ALKINSRPTK2IGF1RMET | |
| SCHEMBL2592584 | 0.84 | MAPK3 (0.71) | ALKINSRPTK2IGF1RMET | |
| SCHEMBL31276403 | 0.84 | ALK (0.84) | ALKINSRPTK2IGF1RMET | |
| SCHEMBL25574941 | 0.84 | ALK (0.69) | ALKINSRPTK2IGF1RMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116969897-A | Sulfonamide compound, preparation method and application thereof, and pharmaceutical composition | 北京大学 | 2023-10-31 | — | — | CN | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| WO-2011140338-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140338-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | ALK 911/4885INSR 428/4885PTK2 29/4885 |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | EGFR, ERBB2, BRCA1 | ALK 911/4885INSR 428/4885PTK2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.